Cisplatin vs. Cetuximab: Which is the Better Treatment for Head and Neck Cancer?
"A large study sheds light on the comparative effectiveness of two common chemoradiation therapies for head and neck cancer, offering crucial insights for treatment decisions."
Head and neck cancers are a significant health concern, with tens of thousands of new cases diagnosed each year. A common treatment approach for these cancers, particularly when they are locally or regionally advanced, involves a combination of radiation therapy (RT) and systemic therapy to improve cancer control and survival rates.
Cisplatin and cetuximab are two systemic therapies frequently used alongside radiation. Cisplatin, a platinum-based chemotherapy drug, has long been a standard option. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), offers an alternative, especially for patients who may not tolerate cisplatin well. However, it has been unclear which of these therapies provides superior outcomes.
A recent study delved into this question by comparing the effectiveness of cisplatin and cetuximab when administered concurrently with radiation therapy for head and neck cancers. Using data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, researchers analyzed a large, national cohort of patients to assess real-world treatment patterns and survival outcomes.
Cisplatin-Based Chemoradiotherapy as Standard Care
For locally advanced squamous cell head and neck cancer, definitive local therapy—surgery and/or radiation—remains a key part of initial treatment, and the disease can still have high curative potential pmc.ncbi.nlm.nih.gov. Concurrent chemoradiotherapy with high-dose cisplatin is described as the standard treatment for locally advanced head and neck squamous cell carcinoma onlinelibrary.wiley.com. Cisplatin is commonly given with radiation either as a high-dose bolus every three weeks or as a lower dose weekly, but the preferred schedule remains controversial sciencedirect.com.
Cetuximab Linked to Higher Cancer-Specific Mortality
The study, encompassing 1,395 patients with locoregionally advanced squamous cell carcinomas, revealed a significant difference in cancer-specific mortality (CSM) between the two treatment groups. Patients treated with cetuximab alongside radiation had a notably higher CSM compared to those who received cisplatin with radiation. Specifically, at three years, 39% of the cetuximab group had died from head and neck cancer, compared to only 25% in the cisplatin group.
- Study Findings: A retrospective analysis of 1,395 patients using SEER-Medicare data compared cisplatin and cetuximab in combination with definitive radiotherapy for head and neck cancers.
- Primary Outcome: Head and neck cancer-specific mortality (CSM).
- Key Result: Cetuximab was associated with significantly higher CSM compared to cisplatin.
- Adjustments: Propensity score matching and multivariable regression were used to adjust for differences in patient characteristics.
- Toxicity Analysis: Cetuximab was associated with less dysphagia, more dermatitis, and similar rates of mucositis.
Evidence on Cetuximab Compared With Other Approaches
A National Cancer Database analysis reported decreased overall survival among patients with locally advanced head and neck cancer receiving definitive radiotherapy with concurrent cetuximab. Its findings were consistent with subsequent studies reporting cetuximab-radiotherapy as inferior to chemoradiotherapy, and the article notes that two recently completed randomized trials in HPV-positive oropharyngeal squamous cell carcinoma also found inferior overall survival with cetuximab-radiotherapy doi.org. Separately, a report on concurrent carboplatin and paclitaxel with definitive radiation cites population-based analyses and retrospective series in which carboplatin-based radiation was associated with better overall survival or disease control than cetuximab-based radiation doi.org.
Cisplatin Eligibility and Treatment Limitations
Cisplatin use in head and neck squamous cell carcinoma is limited by toxicity and acquired resistance, making prescribing decisions multifactorial pmc.ncbi.nlm.nih.gov. For locoregionally advanced disease, chemoradiotherapy is described as an effective nonsurgical primary treatment or as an adjuvant treatment after curative resection frontiersin.org. These limitations mean cisplatin-based treatment is not suitable for every patient, even though chemoradiotherapy remains an established treatment approach.
Implications for Treatment Decisions
This study, with its substantial sample size and national scope, suggests that cisplatin may be the preferred chemotherapeutic agent when combined with radiation for head and neck cancers. The findings highlight the importance of carefully considering the potential risks and benefits of each treatment option.
The Dose Schedule Remains an Open Question
Cisplatin-based chemoradiotherapy is identified as standard treatment for locally advanced head and neck squamous cell carcinoma, but the optimal cisplatin schedule remains debated. A 2025 systematic review and meta-analysis set out to compare weekly cisplatin at 30–50 mg/m² with triweekly cisplatin at 100 mg/m² every three weeks across treatment compliance, efficacy, and toxicity mdpi.com. A 2024 cohort study evaluated how the number of weekly cisplatin cycles was associated with outcomes in patients receiving chemoradiation for head and neck cancer jamanetwork.com. Together, these sources frame dosing and treatment exposure as questions for evidence-based evaluation rather than establishing a single universally preferred schedule.
Balancing Survival and Toxicity as Treatment Evolves
The ASCO Daily News identifies an unmet need in HPV-positive locoregionally advanced head and neck squamous cell carcinoma: improving survival while mitigating toxicity, with cisplatin-based chemoradiation remaining the backbone of multimodality treatment dailynews.ascopubs.org. It reports that de-escalation may be feasible in selected patients and that an induction chemotherapy–based paradigm is a promising tool. A 2026 overview also highlights differences in treatment paradigms for HPV-positive and HPV-negative disease, the evolving role of immunotherapy, and new perioperative approaches oncbrothers.com.
While cetuximab may be better tolerated in some patients due to its association with less dysphagia, the increased risk of cancer-specific mortality raises concerns. Clinicians should weigh these factors, along with individual patient characteristics, when making treatment decisions.
Further research is needed to confirm these findings and explore the underlying reasons for the observed differences in survival. Ongoing randomized trials comparing cisplatin-based and cetuximab-based chemoradiation may provide additional clarity in the future.